WO2023153762A1 - 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도 - Google Patents

멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도 Download PDF

Info

Publication number
WO2023153762A1
WO2023153762A1 PCT/KR2023/001712 KR2023001712W WO2023153762A1 WO 2023153762 A1 WO2023153762 A1 WO 2023153762A1 KR 2023001712 W KR2023001712 W KR 2023001712W WO 2023153762 A1 WO2023153762 A1 WO 2023153762A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
acid
compound
pharmaceutically acceptable
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/001712
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
박희동
황혜경
여수진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Chem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chem Ltd filed Critical LG Chem Ltd
Priority to US18/837,125 priority Critical patent/US20250134898A1/en
Priority to JP2024547302A priority patent/JP2025505229A/ja
Priority to CA3248118A priority patent/CA3248118A1/en
Priority to EP23753110.8A priority patent/EP4461297A4/en
Priority to CN202380032193.6A priority patent/CN119300835A/zh
Priority to AU2023218785A priority patent/AU2023218785A1/en
Publication of WO2023153762A1 publication Critical patent/WO2023153762A1/ko
Anticipated expiration legal-status Critical
Priority to MX2024009854A priority patent/MX2024009854A/es
Priority to CONC2024/0011882A priority patent/CO2024011882A2/es
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a compound of Formula 1 or a pharmaceutically acceptable salt thereof to treat rare genetic obesity diseases associated with the melanocortin-4 receptor (MC4R) pathway, particularly proopiomelanocortin (POMC) deficiency It relates to the use for the purpose of preventing or treating related rare genetic obesity diseases:
  • R1 is C 2 -C 5 alkyl.
  • the melanocortin receptor is a type of G-protein-coupled receptor (GPCR).
  • GPCR G-protein-coupled receptor
  • the main role of G-proteins is to activate second messengers to signal cell responses to many physiological stimuli through signal transduction. Adjust. Five types of melanocortin receptors have been identified so far.
  • MC1R is expressed in melanocytes and macrophages, and melanocytes determine the color of skin and hair by regulating melanin pigment.
  • MC2R is expressed in the adrenal gland and adipose tissue, and its mediating function in the regulation of adrenal hormone secretion by adrenocorticotropic hormone in the adrenal gland is well known.
  • MC3R, MC4R and MC5R are thought to mediate central nervous action by melanocortin peptides that are expressed not only in nerve terminals but also in the brain and have effects on behavior, learning, memory, appetite, development and regeneration of nerves, and the like.
  • MC3R is known to be involved in erectile dysfunction and inflammatory response
  • MC4R is known to be involved in obesity and diabetes, and studies on the action specificity of each receptor are being actively conducted (MacNeil DJ et al., Eur J Pharmacol 2002, 450, 93 ).
  • appetite suppressants that act on the central nervous system are the main types, and among them, drugs that regulate the action of neurotransmitters (eg, phentermine, mazindol, lorcaserin, fluoxetine, and sibutramine) were mostly. .
  • neurotransmitters eg, phentermine, mazindol, lorcaserin, fluoxetine, and sibutramine
  • melanocortin agonist is a neuropeptide, not a neurotransmitter.
  • MC4R knockout (KO) mice it suppresses appetite without affecting other physiological functions. It can have an advantage as a point of action in that it can induce only weight loss through
  • the present invention relates to a compound of Formula 1 or a pharmaceutically acceptable salt thereof to treat rare genetic obesity diseases associated with the melanocortin-4 receptor (MC4R) pathway, particularly proopiomelanocortin (POMC) deficiency It is intended to provide use for use in the prevention or treatment of an associated rare genetic obesity disorder:
  • M4R melanocortin-4 receptor
  • POMC proopiomelanocortin
  • R1 is C 2 -C 5 alkyl.
  • the present invention is a medicament for preventing or treating rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency, comprising a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
  • R1 is C 2 -C 5 alkyl.
  • the present invention relates to a rare genetic disorder associated with proopiomelanocortin (POMC) deficiency, comprising a therapeutically effective amount of the compound of Formula 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. It provides a pharmaceutical composition for the prevention or treatment of obesity diseases.
  • POMC proopiomelanocortin
  • the present invention includes administering a therapeutically effective amount of the compound of Formula 1 or a pharmaceutically acceptable salt thereof to a subject to be treated, a rare genetic obesity disease associated with propiomelanocortin (POMC) deficiency.
  • POMC propiomelanocortin
  • the present invention provides a use of the compound of Formula 1 or a pharmaceutically acceptable salt thereof for preventing or treating a rare genetic obesity disease associated with proopiomelanocortin (POMC) deficiency.
  • POMC proopiomelanocortin
  • a rare genetic obesity disease associated with propiomelanocortin (POMC) deficiency comprising a therapeutically effective amount of the compound of Formula 1 or a pharmaceutically acceptable salt thereof.
  • POMC propiomelanocortin
  • a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof, associated with proopiomelanocortin (POMC) deficiency comprising a pharmaceutically acceptable carrier.
  • POMC proopiomelanocortin
  • the compound of Formula 1 is N -((3 S ,5 S )-1-((3 S ,4 R )-1-( tert -butyl)-4 of Formula 2 -(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)- N -((1 s ,4 R )-4- methylcyclohexyl)isobutyramide:
  • the pharmaceutically acceptable salt is selected from inorganic acids such as, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid and the like, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, and the like.
  • inorganic acids such as, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid and the like, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, and the like.
  • the pharmaceutically acceptable salt may be selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid.
  • the pharmaceutically acceptable salt is a hydrochloride salt.
  • the hydrochloride salt of the compound of Formula 1 may be prepared according to Reaction Scheme 1 below. However, those skilled in the art can prepare the compound of Formula 1 by various methods based on the structure of Formula 1.
  • R2 is C 1 -C 5 alkyl
  • R3 is C 3 -C 8 cycloalkyl unsubstituted or substituted with 1 or 2 C 1 -C 5 alkyl;
  • R4 and R5 are each independently hydrogen or halogen.
  • the compound of Formula 1 can efficiently prevent or treat rare genetic obesity diseases associated with proopiomelanocortin (POMC) deficiency.
  • Proopiomelanocortin (POMC) is a precursor polypeptide with 241 amino acid residues, synthesized in the anterior and middle pituitary glands, and melanocyte-stimulating hormone (MSH), endorphin, adrenal cortex It serves as a precursor to several peptide hormones, such as corticotrophin.
  • MSH melanocyte-stimulating hormone
  • Alpha-MSH a ligand of the melanocortin-4 receptor (MC4R) acts upstream of MC4R.
  • therapeutically effective amount for an individual subject means an amount sufficient to achieve the pharmacological effect described above, that is, a therapeutic effect, and the amount of the compound is related to the condition and It will depend on its severity, mode of administration, and age of the subject to be treated, but can be determined by those skilled in the art based on their own knowledge.
  • the therapeutically effective dosage of the compound of Formula 1 for example, the dosage required for adult treatment, is usually in the range of about 0.1 to 500 mg per day depending on the frequency and intensity of administration.
  • a total dose of about 0.1 to 300 mg per day divided into single doses will usually suffice, but in some patients higher daily doses may be desirable.
  • pharmaceutical composition may include other chemical components such as carriers, diluents, excipients and the like in addition to the active compound according to the present invention. Accordingly, the pharmaceutical composition may include a pharmaceutically acceptable carrier, diluent, excipient, or a combination thereof, if necessary.
  • a pharmaceutical composition facilitates administration of an active compound into an organism. A variety of techniques for administering the compound exist, including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
  • carrier means a compound that facilitates the introduction of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the introduction of many organic compounds into the cells or tissues of living organisms.
  • diluent is defined as a compound that is diluted in water to dissolve the compound as well as to stabilize the biologically active form of the subject compound.
  • a salt dissolved in a buffer is used as a diluent in the art.
  • a commonly used buffer is phosphate buffered saline, which mimics the salt form of human body fluids. Because buffer salts can control the pH of a solution at low concentrations, buffered diluents rarely modify the biological activity of a compound.
  • pharmaceutically acceptable means a property that does not impair the biological activity and physical properties of a compound.
  • the compound may be formulated into various pharmaceutical dosage forms as desired.
  • the active ingredient specifically the compound of Formula 1 or a pharmaceutically acceptable salt thereof, together with various pharmaceutically acceptable carriers that may be selected according to the formulation to be prepared.
  • the pharmaceutical composition according to the present invention may be formulated into an injection preparation, an oral preparation, etc., as desired.
  • the compound of the present invention may be formulated by a known method using known pharmaceutical carriers and excipients and put into a unit dosage form or a multi-dose container.
  • Formulations may be in the form of solutions, suspensions or emulsions in oil or aqueous media, and may contain conventional dispersing agents, suspending agents or stabilizing agents. In addition, for example, it may be in the form of a dry powder that is used by dissolving it in sterile, pyrogen-free water before use.
  • the compounds of the present invention may also be formulated in suppository form using conventional suppository bases such as cocoa butter or other glycerides.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules, and capsules and tablets are particularly useful. Tablets and pills are preferably prepared with an enteric coating.
  • Solid dosage forms can be prepared by mixing a compound of the present invention with one or more inert diluents such as sucrose, lactose, starch and the like and a carrier such as a lubricant such as magnesium stearate, a disintegrant, a binder and the like.
  • it may be formulated into a transdermal dosage form, and may be formulated into, for example, a lotion, ointment, gel, cream, patch, or spray.
  • the medicament or pharmaceutical composition may be an oral dosage form.
  • prevention means reducing or eliminating the possibility of getting a disease.
  • treatment means stopping, delaying, or mitigating the progression of a disease when used in a subject exhibiting symptoms of disease.
  • the drug or pharmaceutical composition according to the present invention is a rare genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particularly a rare genetic obesity disease associated with proopiomelanocortin (POMC) deficiency. can be effectively prevented or treated.
  • M4R melanocortin-4 receptor
  • POMC proopiomelanocortin
  • 1 is a graph showing the results of measuring anti-obesity efficacy in a high-fat diet POMC heterozygous deficient mouse model (HFD POMC heterozygous deficient mouse).
  • Figure 2 is a graph showing the results of measuring the anti-obesity (anti-obesity) efficacy in a high-fat diet POMC homozygous deficient mouse model (HFD POMC homozygous deficient mouse).
  • the title compound was obtained through the following steps A, B, C and D.
  • Step A Methyl (2 S ,4 S )-1-((3 S ,4 R )-One-( tert -butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-4-( N -((One s ,4 R Preparation of )-4-methylcyclohexyl)isobutyramido)pyrrolidine-2-carboxylate
  • Step B (2 S ,4 S )-1-((3 S ,4 R )-One-( tert -butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-4-( N -((One s ,4 R Preparation of )-4-methylcyclohexyl)isobutyramido)pyrrolidine-2-carboxylic acid
  • reaction solution was concentrated under reduced pressure. After dissolving the concentrate in dichloromethane, insoluble solids were filtered through a paper filter. The filtrate was concentrated under reduced pressure to obtain crude (38.4 g, 99%), which was used in the next step without purification.
  • Step C N -((3 S ,5 S )-1-((3 S ,4 R )-One-( tert -Butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)- N -((One s ,4 R Preparation of )-4-methylcyclohexyl)isobutyramide
  • Step D N -((3 S ,5 S )-1-((3 S ,4 R )-One-( tert -Butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)- N -((One s ,4 R Preparation of )-4-methylcyclohexyl)isobutyramide hydrochloride
  • Proopiomelanocortin is a precursor polypeptide of alpha-MSH, a ligand of the melanocortin-4 receptor (MC4R), and acts upstream of the melanocortin-4 receptor.
  • M4R melanocortin-4 receptor
  • Pomc knock-out mice in which the protein is not properly expressed, are a model that reflects POMC deficiency obesity, a genetic obesity disease, and show abnormal metabolic disease-related phenotypes such as hyperphagia and severe obesity.
  • test compound N -( (3 S ,5 S )-1-((3 S ,4 R )-1-( tert -butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine -4-carbonyl)pyrrolidin-3-yl) -N -(( 1s , 4R )-4-methylcyclohexyl)isobutyramide hydrochloride (hereinafter referred to as “test compound”) at 10 mg/kg Alternatively, the anti-obesity effect was confirmed by administration at a dose of 30 mg/kg for about 3 weeks, and the results are shown in FIG. 1.
  • Pomc homozygous knock-out mice which do not express the Pomc gene encoding proopiomelanocortin (POMC) are fed a 45 kcal% high-fat diet (diet with 45 kcal% fat) while administering 10 mg/kg or 10 mg/kg of the test compound. It was administered for about 10 days at a dose of 30 mg/kg to confirm the anti-obesity efficacy, and the results are shown in FIG. 2 .
  • POMC proopiomelanocortin
  • test compound of the present invention exhibits an excellent anti-obesity effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/KR2023/001712 2022-02-08 2023-02-07 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도 Ceased WO2023153762A1 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US18/837,125 US20250134898A1 (en) 2022-02-08 2023-02-07 Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
JP2024547302A JP2025505229A (ja) 2022-02-08 2023-02-07 稀少遺伝性肥満症の予防または治療におけるメラノコルチン-4受容体アゴニストの使用
CA3248118A CA3248118A1 (en) 2022-02-08 2023-02-07 USE OF A MELANOCORTIN-4 RECEPTOR AGONIST IN THE PREVENTION OR TREATMENT OF A RARE GENETIC OBESITY DISEASE
EP23753110.8A EP4461297A4 (en) 2022-02-08 2023-02-07 USE OF MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE PREVENTION OR TREATMENT OF RARE GENETIC OBESITY DISEASE
CN202380032193.6A CN119300835A (zh) 2022-02-08 2023-02-07 黑皮质素-4受体激动剂在预防或治疗罕见遗传性肥胖疾病中的用途
AU2023218785A AU2023218785A1 (en) 2022-02-08 2023-02-07 Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
MX2024009854A MX2024009854A (es) 2022-02-08 2024-08-12 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genetica rara de la obesidad
CONC2024/0011882A CO2024011882A2 (es) 2022-02-08 2024-08-30 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08
KR10-2022-0016377 2022-02-08

Publications (1)

Publication Number Publication Date
WO2023153762A1 true WO2023153762A1 (ko) 2023-08-17

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/001712 Ceased WO2023153762A1 (ko) 2022-02-08 2023-02-07 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068770A1 (en) * 2023-09-27 2025-04-03 Lg Chem, Ltd. Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007930A1 (en) * 2006-07-14 2008-01-17 Lg Life Sciences Ltd. Melanocortin receptor agonists
KR20210055624A (ko) * 2019-11-07 2021-05-17 주식회사 엘지화학 멜라노코르틴-4 수용체 작용제
WO2022158868A1 (ko) * 2021-01-21 2022-07-28 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007930A1 (en) * 2006-07-14 2008-01-17 Lg Life Sciences Ltd. Melanocortin receptor agonists
KR20210055624A (ko) * 2019-11-07 2021-05-17 주식회사 엘지화학 멜라노코르틴-4 수용체 작용제
WO2022158868A1 (ko) * 2021-01-21 2022-07-28 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 용도

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEN, C. JIANG, W. TRAN, J.A. TUCCI, F.C. FLECK, B.A. MARKISON, S. WEN, J. MADAN, A. HOARE, S.R. FOSTER, A.C. : "Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 18, no. 1, 4 November 2007 (2007-11-04), Amsterdam NL , pages 129 - 136, XP022410870, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2007.10.115 *
CLÉMENT KARINE, VAN DEN AKKER ERICA, ARGENTE JESÚS, BAHM ALLISON, CHUNG WENDY K, CONNORS HILLORI, DE WAELE KATHLEEN, FAROOQI I SAD: "Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials", LANCET DIABETES ENDOCRINOL, vol. 8, no. 12, 1 December 2020 (2020-12-01), pages 960 - 970, XP009548043 *
HINNEY A ET AL., J CLIN ENDOCRINOL METAB, vol. 84, no. 4, 1990, pages 1483
HUSZAR D ET AL., CELL, vol. 88, no. 1, 1997, pages 131
LU DWILLARD D ET AL., NATURE, vol. 371, no. 6500, 1994, pages 799
MACNEIL DJ ET AL., EUR J PHARMACOL, vol. 450, 2002, pages 93
See also references of EP4461297A4
TOOKE BENJAMIN P., YU HUI, ADAMS JESSICA M., JONES GRAHAM L., SUTTON-KENNEDY TALISHA, MUNDADA LAKSHMI, QI NATHAN R., LOW MALCOLM J: "Hypothalamic POMC or MC4R deficiency impairs counterregulatory responses to hypoglycemia in mice", MOLECULAR METABOLISM, vol. 20, 1 February 2019 (2019-02-01), pages 194 - 204, XP093083863, ISSN: 2212-8778, DOI: 10.1016/j.molmet.2018.11.004 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068770A1 (en) * 2023-09-27 2025-04-03 Lg Chem, Ltd. Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications

Also Published As

Publication number Publication date
JP2025505229A (ja) 2025-02-21
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
EP4461297A4 (en) 2025-04-09
CL2024002389A1 (es) 2025-01-31
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
AR128463A1 (es) 2024-05-08
CO2024011882A2 (es) 2025-01-23
TWI838114B (zh) 2024-04-01
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16
MX2024009854A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
WO2023191408A1 (ko) 비만의 예방 또는 치료용 병용 요법
WO2022158868A1 (ko) 멜라노코르틴-4 수용체 효능제의 용도
EP4461297A1 (en) Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
WO2022139406A1 (ko) 멜라노코르틴-4 수용체의 선택적 항진제로서의 용도
EP4299572A1 (en) Melanocortin-4 receptor agonist
RU2850792C1 (ru) Применение агониста рецептора меланокортина-4
HK40119184A (en) Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
KR20250108398A (ko) Lepr 이형접합 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
KR20250100260A (ko) Sh2b1 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
WO2025068770A1 (en) Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753110

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: P2024-02046

Country of ref document: AE

Ref document number: 2023753110

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 18837125

Country of ref document: US

Ref document number: 2024547302

Country of ref document: JP

Ref document number: AU23218785

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023753110

Country of ref document: EP

Effective date: 20240807

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/009854

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024016154

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2023218785

Country of ref document: AU

Date of ref document: 20230207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2024/0011882

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 202417067731

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024126253

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202405469X

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202380032193.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 112024016154

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240807

WWP Wipo information: published in national office

Ref document number: 202380032193.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: NC2024/0011882

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 18837125

Country of ref document: US